{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:24:05Z","timestamp":1777987445243,"version":"3.51.4"},"reference-count":100,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2026,2,11]]},"DOI":"10.1080\/1750743x.2026.2644799","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:24:36Z","timestamp":1773836676000},"page":"187-203","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy of endometrial cancer: a review of recent advances"],"prefix":"10.1080","volume":"18","author":[{"given":"Kre\u0161imir","family":"Tomi\u0107","sequence":"first","affiliation":[{"name":"University Hospital Center Mostar","place":["Mostar, Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Kati\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Center Zagreb","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Gatalica","sequence":"additional","affiliation":[{"name":"Reference Medicine","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordan","family":"Srkalovi\u0107","sequence":"additional","affiliation":[{"name":"University of Michigan Health-Sparrow Herbert-Herman Cancer Center","place":["Lansing, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja Pezer","family":"Naletili\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Center Mostar","place":["Mostar, Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vrdoljak","sequence":"additional","affiliation":[{"name":"University Hospital Center Split","place":["Split, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-7265","authenticated-orcid":false,"given":"Semir","family":"Vrani\u0107","sequence":"additional","affiliation":[{"name":"Qatar University","place":["Doha, Qatar"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.09.002"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1545-4279"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00323-3"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1835"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000075"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/cej.0b013e328329d830"},{"key":"e_1_3_5_9_1","unstructured":"Online Mendelian Inheritance in Man OMIM\u00ae. Lynch syndrome; LYNCH. MIM number: 614350 [internet]. Baltimore (MD): Johns Hopkins University; \u00a91966\u20132025 [cited 2025 Jul 16]. Available from: https:\/\/www.omim.org\/entry\/614350"},{"key":"e_1_3_5_10_1","unstructured":"Online Mendelian Inheritance in Man OMIM\u00ae. Cowden syndrome 1; CWS1. MIM Number: 158350 [Internet]. Baltimore (MD): Johns Hopkins University; \u00a91966\u20132025 [cited 2025 Aug 5]. Available from: https:\/\/www.omim.org\/entry\/158350"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.10.010"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005478"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.009"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00549"},{"key":"e_1_3_5_16_1","unstructured":"Refining adjuvant treatment in endometrial cancer based on molecular features (RAINBO) [internet]. [cited 2025 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05255653"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00612-6"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01015-z"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00283"},{"key":"e_1_3_5_20_1","unstructured":"College of American Pathologists. Endometrial carcinoma testing for MMR MSI or both [internet]. 2020 [cited 2025 Aug 10]. Available from: https:\/\/documents.cap.org\/documents\/cap-31-mmr-msi-endometrial-carcinoma-testing-2020.pdf"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.12"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5372"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0057"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13338"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002256"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100085"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.82"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.028"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004864"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5373"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107269"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.06.008"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"e_1_3_5_36_1","unstructured":"Endometrial cancer patients MMR deficient comparing chemotherapy vs dostarlimab in first line (DOMENICA) [internet]. [cited 2025 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05201547"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01887"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035616"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00497-5"},{"key":"e_1_3_5_42_1","unstructured":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors. 2020 [cited 2025 Aug 30]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14969"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01421-4"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002230"},{"key":"e_1_3_5_46_1","unstructured":"Summary of product characteristics [internet]: European Medicines Agency. 2018 [cited 2025 Aug 10]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20180621141215\/anx_141215_en.pdf"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_5_48_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site-agnostic indication [internet]. FDA; 2017 [cited 2025 Aug 10]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3915"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002255"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01021"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01021"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00016-5"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.546"},{"key":"e_1_3_5_56_1","volume-title":"Presented at: Society of Gynecologic Oncology 2024 Annual Meeting for Womens Cancer","author":"Eskander RN","year":"2024","unstructured":"Eskander RN, Sill M, Miller A, et al. Overall survival, progression-free survival by PD-L1 status, and blinded independent central review results with pembrolizumab plus carboplatin\/paclitaxel (CP) versus placebo plus CP in patients with endometrial cancer: results from the NRG GY018 trial. In: Presented at: Society of Gynecologic Oncology 2024 Annual Meeting for Womens Cancer; San Diego, CA; 2024 Mar 15\u201318."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00334-6"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.092"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5503"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.037"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103540"},{"key":"e_1_3_5_62_1","unstructured":"Study of pembrolizumab (MK-3475) versus chemotherapy in mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma (MK-3475-C93\/KEYNOTE-C93\/GOG-3064\/ENGOT-en15) [Internet]. [cited 2025 Aug 10]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05173987"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01326"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2242"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071162"},{"key":"e_1_3_5_66_1","unstructured":"Testing the addition of the immunotherapy drug pembrolizumab to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer [Internet]. [cited 2025 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04214067"},{"key":"e_1_3_5_67_1","unstructured":"SATELLITE study (feasibility safety and efficacy of dostarlimab in early-stage deficient endometrial cancer) (SATELLITE) [Internet]. [cited 2025 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06278857"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52098-8"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111448"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5952"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.11.028"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004233"},{"issue":"3","key":"e_1_3_5_74_1","first-page":"A8","article-title":"Atezolizumab and bevacizumab in recurrent endometrial cancer: a phase II, multi-institutional trial","volume":"32","author":"Fuh K","year":"2022","unstructured":"Fuh K, Richardson D, Arend R, et al. Atezolizumab and bevacizumab in recurrent endometrial cancer: a phase II, multi-institutional trial. Int J Gynecol Cancer. 2022;32(Suppl 3):A8.","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.039"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02627"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.09.010"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.12.010"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1919"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101703"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.007"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03566-1"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2022.7953"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015233"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0654"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020401"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103538"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115329"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.05.016"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2018.08.021"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.05.022"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.016"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103539"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT008"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1368103"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells14171404"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03371-1"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.12.025"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49017-2"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1750743X.2026.2644799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:35:19Z","timestamp":1777984519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1750743X.2026.2644799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,11]]}},"alternative-id":["10.1080\/1750743X.2026.2644799"],"URL":"https:\/\/doi.org\/10.1080\/1750743x.2026.2644799","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}